Estelle Ayme-Dietrich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Estelle Ayme-Dietrich has a total of 150 co-authors. Here are the top co-authors by number of shared publications:
- Laurent Monassier
Laboratoire de Pharmacologie et Toxicologie Neurocardiovasculaire, Unité de recherche 7296, Faculté de Médecine de Maïeutique et des Sciences de la Santé, Centre de Recherche en Biomédecine de Strasbourg (CRBS), 67085, Strasbourg, France
11 shared publications - Roland Lawson
University of Limoges, Inserm U1248, Pharmacology & Transplantation, Limoges, France
6 shared publications - Luc Maroteaux
Sorbonne University
5 shared publications Laurent Monassier
Laboratoire de Pharmacologie et Toxicologie Neurocardiovasculaire, UR7296, Université de Strasbourg, Strasbourg, France
4 shared publicationsBernard Gasser
Laboratoire de Pathologie, Centre Hospitalier Emile Muller, Mulhouse, France
3 shared publicationsGaëlle Aubertin-Kirch
Laboratoire de Neurobiologie et Pharmacologie Cardiovasculaire EA7296, Faculté de Médecine, Fédération de Médecine Translationnelle de Strasbourg, Université et Centre Hospitalier de Strasbourg, Strasbourg, France
3 shared publications
Latest Publications
- Open Access
- 5 October 2026
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 18 (11) , 4227-4259
Ebselen restores mitochondrial function through metabolic rewiring in Barth syndrome and related mitochondrial diseases
Despite major advances in the genetic diagnosis of mitochondrial disorders, effective disease-modifying therapies remain scarce. Here, we identify ebselen (EBS) as a promising therapeutic candidate through a phenotypic drug screen in a yeast model of Barth syndrome, a cardiomyopathy caused by defective cardiolipin maturation. EBS improved oxidative phosphorylation-dependent growth across diverse fungal models of mitochondrial diseases, including defects in complex I, complex IV, mitochondrial DNA maintenance, mitochondrial translation, and ATP synthase. Therapeutic efficacy was further validated in patient-derived fibroblasts, iPSC-derived cardiomyocytes, and a cardiolipin-deficient mouse model. Mechanistically, EBS acts independently of its established antioxidant activity by engaging a conserved metabolic program that suppresses cytosolic translation while stimulating pyruvate dehydrogenase-dependent tricarboxylic acid cycle activity, thereby improving proteostasis and mitochondrial bioenergetic function. These effects are likely coordinated through lysosome-associated mTOR signaling, consistent with the localization of EBS to lysosomes and its colocalization with mTOR. Together, our findings identify a conserved mechanism for enhancing mitochondrial function and establish ebselen as a strong candidate for therapeutic repurposing in Barth syndrome and a broad spectrum of inherited mitochondrial disorders.
- 5 October 2026
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 18 (11) , 4227-4259
Open AccessEbselen restores mitochondrial function through metabolic rewiring in Barth syndrome and related mitochondrial diseases
Despite major advances in the genetic diagnosis of mitochondrial disorders, effective disease-modifying therapies remain scarce. Here, we identify ebselen (EBS) as a promising therapeutic candidate through a phenotypic drug screen in a yeast model of Barth syndrome, a cardiomyopathy caused by defective cardiolipin maturation. EBS improved oxidative phosphorylation-dependent growth across diverse fungal models of mitochondrial diseases, including defects in complex I, complex IV, mitochondrial DNA maintenance, mitochondrial translation, and ATP synthase. Therapeutic efficacy was further validated in patient-derived fibroblasts, iPSC-derived cardiomyocytes, and a cardiolipin-deficient mouse model. Mechanistically, EBS acts independently of its established antioxidant activity by engaging a conserved metabolic program that suppresses cytosolic translation while stimulating pyruvate dehydrogenase-dependent tricarboxylic acid cycle activity, thereby improving proteostasis and mitochondrial bioenergetic function. These effects are likely coordinated through lysosome-associated mTOR signaling, consistent with the localization of EBS to lysosomes and its colocalization with mTOR. Together, our findings identify a conserved mechanism for enhancing mitochondrial function and establish ebselen as a strong candidate for therapeutic repurposing in Barth syndrome and a broad spectrum of inherited mitochondrial disorders.
- Open Access
- 25 June 2026
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (9) , e70660-3264
A descriptive case series of hepatotoxicity associated with CFTR modulators and possible relevance of pharmacogenetic polymorphisms in cystic fibrosis patients
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are widely used in patients with cystic fibrosis and significantly improve respiratory function and quality of life. However, their effectiveness may be limited by liver damage, which sometimes leads to treatment discontinuation, and the mechanisms underlying this remain poorly understood. This case series explores the role of genetic polymorphisms affecting the enzymes and transporters involved in their pharmacokinetics, as well as detoxification mechanisms (CYP3A4/CYP3A5/ABCB1/SLCO1B1/GSTP1/GSTM1/GSTT1). Six cases of hepatotoxicity under CFTR modulators were assessed using the RECAM score. Among the genetic polymorphisms assessed, CYP3A4*22 (rs35599367) allele had higher allele frequency than in the European population, which usually does not express CYP3A5. This genetic variant, reducing CYP3A activity, could decrease the elimination of CFTR modulators and increase the risk of liver toxicity. Other genetic factors may also be involved. Further studies are needed to confirm these results.
- 25 June 2026
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (9) , e70660-3264
Open AccessA descriptive case series of hepatotoxicity associated with CFTR modulators and possible relevance of pharmacogenetic polymorphisms in cystic fibrosis patients
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are widely used in patients with cystic fibrosis and significantly improve respiratory function and quality of life. However, their effectiveness may be limited by liver damage, which sometimes leads to treatment discontinuation, and the mechanisms underlying this remain poorly understood. This case series explores the role of genetic polymorphisms affecting the enzymes and transporters involved in their pharmacokinetics, as well as detoxification mechanisms (CYP3A4/CYP3A5/ABCB1/SLCO1B1/GSTP1/GSTM1/GSTT1). Six cases of hepatotoxicity under CFTR modulators were assessed using the RECAM score. Among the genetic polymorphisms assessed, CYP3A4*22 (rs35599367) allele had higher allele frequency than in the European population, which usually does not express CYP3A5. This genetic variant, reducing CYP3A activity, could decrease the elimination of CFTR modulators and increase the risk of liver toxicity. Other genetic factors may also be involved. Further studies are needed to confirm these results.
- 1 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Implication de la sérotonine et des récepteurs 5-HT 2A/2B dans le remodelage des valves cardiaques et des bioprothèses valvulaires
L’hypothèse d’un lien entre valvulopathies et surexpression du système sérotoninergique fait suite aux lésions valvulaires observées lors de tumeurs carcinoïdes (taux sanguins de 5-HT élevés) et lors de l’utilisation chronique d’agonistes sérotoninergiques 5-HT2 (comme les dérivés de l’ergot de seigle, les fenfluramines). Le dogme actuel repose sur un effet prolifératif de la sérotonine, activant des cellules résidentes valvulaires, mais ne suffit pas à expliquer la dégénérescence de bioprothèses acellulaires. Nos travaux ont permis d’identifier des cellules progénitrices endothéliales (CD34+/CD309+), exprimant les récepteurs 5-HT2A et 5-HT2B, au sein de lésions valvulaires humaines aortiques et mitrales, quelle que soit l’étiologie de leur dégénérescence. Ils ont permis de mettre en évidence un rôle double de la sérotonine dans la dégénérescence valvulaire : 1) la stimulation des récepteurs 5-HT2B contribue à la mobilisation sanguine des progéniteurs CD34+ (recrutés à partir de la moelle osseuse, et migrant dans le tissu valvulaire), 2) le rôle des récepteurs 5-HT2 dans la transdifférenciation des progéniteurs endothéliaux en cellules activées, au sein de la matrice valvulaire. La suite de ce travail permettra de développer 1) un biomarqueur prédictif d’atteinte valvulaire, dans des populations à haut risque, 2) de développer un modèle cellulaire de valvulopathie pour étudier les mécanismes impliqués dans le remodelage valvulaire et leurs voies de signalisation, et 3) de déterminer des cibles thérapeutiques autour du système sérotoninergique, permettant de ralentir la progression des lésions et retarder l’exérèse chirurgicale, seule alternative actuelle.Abstract
- 1 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Implication de la sérotonine et des récepteurs 5-HT 2A/2B dans le remodelage des valves cardiaques et des bioprothèses valvulaires
L’hypothèse d’un lien entre valvulopathies et surexpression du système sérotoninergique fait suite aux lésions valvulaires observées lors de tumeurs carcinoïdes (taux sanguins de 5-HT élevés) et lors de l’utilisation chronique d’agonistes sérotoninergiques 5-HT2 (comme les dérivés de l’ergot de seigle, les fenfluramines). Le dogme actuel repose sur un effet prolifératif de la sérotonine, activant des cellules résidentes valvulaires, mais ne suffit pas à expliquer la dégénérescence de bioprothèses acellulaires. Nos travaux ont permis d’identifier des cellules progénitrices endothéliales (CD34+/CD309+), exprimant les récepteurs 5-HT2A et 5-HT2B, au sein de lésions valvulaires humaines aortiques et mitrales, quelle que soit l’étiologie de leur dégénérescence. Ils ont permis de mettre en évidence un rôle double de la sérotonine dans la dégénérescence valvulaire : 1) la stimulation des récepteurs 5-HT2B contribue à la mobilisation sanguine des progéniteurs CD34+ (recrutés à partir de la moelle osseuse, et migrant dans le tissu valvulaire), 2) le rôle des récepteurs 5-HT2 dans la transdifférenciation des progéniteurs endothéliaux en cellules activées, au sein de la matrice valvulaire. La suite de ce travail permettra de développer 1) un biomarqueur prédictif d’atteinte valvulaire, dans des populations à haut risque, 2) de développer un modèle cellulaire de valvulopathie pour étudier les mécanismes impliqués dans le remodelage valvulaire et leurs voies de signalisation, et 3) de déterminer des cibles thérapeutiques autour du système sérotoninergique, permettant de ralentir la progression des lésions et retarder l’exérèse chirurgicale, seule alternative actuelle.Abstract
- Open Access
- 25 November 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 117 (2) , 387-397
French‐Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Clinical Use of Mavacamten
Mavacamten, the first drug in the class of β‐cardiac myosin modulator, is used for the treatment of patients with hypertrophic cardiomyopathy. This orally administered drug demonstrates wide interpatient variability in pharmacokinetics parameters, due in part to variant CYP2C19 alleles. Individuals who are CYP2C19 poor metabolizers have increased exposure and are at increased risk of reduced cardiac hypercontractility. To ensure the safety of all patients, European Medicines Agency recommends CYP2C19 preemptive genotyping, and consecutively, to adapt maintenance and initial mavacamten doses, and to manage drug–drug interactions, according to CYP2C19 phenotype. In this article, we summarize evidence from the literature supporting the association between CYP2C19 phenotype and pharmacological features of mavacamten and provide, beyond biologic guidelines, therapeutic recommendations for the use of mavacamten based on CYP2C19 and CYP3A4/CYP3A5 genotype.
- 25 November 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 117 (2) , 387-397
Open AccessFrench‐Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Clinical Use of Mavacamten
Mavacamten, the first drug in the class of β‐cardiac myosin modulator, is used for the treatment of patients with hypertrophic cardiomyopathy. This orally administered drug demonstrates wide interpatient variability in pharmacokinetics parameters, due in part to variant CYP2C19 alleles. Individuals who are CYP2C19 poor metabolizers have increased exposure and are at increased risk of reduced cardiac hypercontractility. To ensure the safety of all patients, European Medicines Agency recommends CYP2C19 preemptive genotyping, and consecutively, to adapt maintenance and initial mavacamten doses, and to manage drug–drug interactions, according to CYP2C19 phenotype. In this article, we summarize evidence from the literature supporting the association between CYP2C19 phenotype and pharmacological features of mavacamten and provide, beyond biologic guidelines, therapeutic recommendations for the use of mavacamten based on CYP2C19 and CYP3A4/CYP3A5 genotype.
- Open Access
- 5 June 2024
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 33 (6) , e5814
Use of methylphenidate and reporting of valvular heart disease: Global pharmacovigilance analysis in children and adults
Introduction: Methylphenidate (MPH) is a common treatment of attention‐deficit/hyperactivity disorder (ADHD). Concern has been raised regarding its cardiovascular safety, partly in relation with its micromolar affinity for the 5‐HT2B receptor, whose activation may result in valvular heart disease (VHD).Methods: To explore the association between the use of MPH and VHD reporting, we performed a disproportionality analysis within the WHO global safety database (VigiBase) using data, since inception until March 6th 2024, from: (i) the full database and (ii) different age groups (children/adolescents 6–17 years; adults 18–64 years). To avoid competition bias, safety reports with amphetamine‐like appetite suppressants were excluded. Disproportionality was expressed using reporting odds‐ratio (ROR) and its 95% confidence interval (CI).Results: Of 29 129 spontaneous reports with MPH, 23 VHD cases (7.9 per 10 000 reports) were identified, including 13 adults and 10 children. Most cases concerned injury on the mitral valve. A disproportionate reporting was observed overall (ROR 1.6, 95% CI 1.1–2.4). Analysis according to age group found that disproportionality in VHD reporting was found in adults only (ROR 2.7, 95% CI 1.6–4.7) but not in children/adolescents (ROR 1.7, 95% CI 0.9–3.2). Furthermore, amongst MPH users only, VHD reporting was higher in adults compared to children (ROR 2.7, 95% CI 1.2–6.3).Conclusion: VHD reporting appears rare with MPH compared to other adverse events and is increased in adults only. Our findings support a potential safety signal of VHD in adults exposed to MPH. A risk in that population cannot be excluded and requires further assessment.
- 5 June 2024
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 33 (6) , e5814
Open AccessUse of methylphenidate and reporting of valvular heart disease: Global pharmacovigilance analysis in children and adults
Introduction: Methylphenidate (MPH) is a common treatment of attention‐deficit/hyperactivity disorder (ADHD). Concern has been raised regarding its cardiovascular safety, partly in relation with its micromolar affinity for the 5‐HT2B receptor, whose activation may result in valvular heart disease (VHD).Methods: To explore the association between the use of MPH and VHD reporting, we performed a disproportionality analysis within the WHO global safety database (VigiBase) using data, since inception until March 6th 2024, from: (i) the full database and (ii) different age groups (children/adolescents 6–17 years; adults 18–64 years). To avoid competition bias, safety reports with amphetamine‐like appetite suppressants were excluded. Disproportionality was expressed using reporting odds‐ratio (ROR) and its 95% confidence interval (CI).Results: Of 29 129 spontaneous reports with MPH, 23 VHD cases (7.9 per 10 000 reports) were identified, including 13 adults and 10 children. Most cases concerned injury on the mitral valve. A disproportionate reporting was observed overall (ROR 1.6, 95% CI 1.1–2.4). Analysis according to age group found that disproportionality in VHD reporting was found in adults only (ROR 2.7, 95% CI 1.6–4.7) but not in children/adolescents (ROR 1.7, 95% CI 0.9–3.2). Furthermore, amongst MPH users only, VHD reporting was higher in adults compared to children (ROR 2.7, 95% CI 1.2–6.3).Conclusion: VHD reporting appears rare with MPH compared to other adverse events and is increased in adults only. Our findings support a potential safety signal of VHD in adults exposed to MPH. A risk in that population cannot be excluded and requires further assessment.
- 2 November 2021
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 37 (11) , 1855-1858
Angiotensin-converting enzyme inhibitor induced angioedema: not always a class effect? A case report and short narrative review
Introduction Bradykinin-mediated angioedema is a rare but potentially fatal adverse event. Angioedema induced by angiotensin-converting enzyme (ACE) inhibitors is generally attributed to an inhibition of bradykinin degradation following ACE inhibition. Clinical studies on ACE inhibitors mainly focus on their efficacy. Few examine their potential to generate undesirable adverse effects, particularly with regard to angioedema. Case description We report here a case of angioedema occurring after ramipril initiation in a patient chronically treated with quinapril. Angioedema subsided spontaneously after ramipril discontinuation and quinapril reintroduction. Discussion and conclusions Our clinical case suggests that despite similar pharmacodynamic properties, quinapril and ramipril do not have the same potential to generate angioedema. To explain this difference, we suggest a potentiation of the effect of bradykinin at the B2 receptor level by ramipril, which does not occur with quinapril. Consequently, angioedema may not always be a class effect of ACE inhibitors.
- 2 November 2021
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 37 (11) , 1855-1858
Angiotensin-converting enzyme inhibitor induced angioedema: not always a class effect? A case report and short narrative review
Introduction Bradykinin-mediated angioedema is a rare but potentially fatal adverse event. Angioedema induced by angiotensin-converting enzyme (ACE) inhibitors is generally attributed to an inhibition of bradykinin degradation following ACE inhibition. Clinical studies on ACE inhibitors mainly focus on their efficacy. Few examine their potential to generate undesirable adverse effects, particularly with regard to angioedema. Case description We report here a case of angioedema occurring after ramipril initiation in a patient chronically treated with quinapril. Angioedema subsided spontaneously after ramipril discontinuation and quinapril reintroduction. Discussion and conclusions Our clinical case suggests that despite similar pharmacodynamic properties, quinapril and ramipril do not have the same potential to generate angioedema. To explain this difference, we suggest a potentiation of the effect of bradykinin at the B2 receptor level by ramipril, which does not occur with quinapril. Consequently, angioedema may not always be a class effect of ACE inhibitors.
- Open Access
- 2 September 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (9) , e0257022
Characterization of the spontaneous degenerative mitral valve disease in FVB mice
Background: The development of new non-surgical treatments dedicated to mitral valve degeneration is limited by the absence of relevant spontaneous and rapidly progressing animal experimental models. Animals: We characterized the spontaneous mitral valve degeneration in two inbred FVB mouse strains compared to C57BL/6J and investigated a contribution of the serotonergic system. Methods: Males and females FVB/NJ and FVB/NRj were compared to the putative C57BL/6J control at 12, 16, 20 and 24 weeks of age. Body weight, systolic blood pressure, heart rate, urinary 5-hydroxyindoleacetic acid (5-HIAA), whole blood and plasma serotonin, tail bleeding time, blood cell count, plasma TGF-β1 and plasma natriuretic peptide concentrations were measured. Myocardium and mitral valves were characterized by histology. mRNA mitral expression of 5-HT2A and 5-HT2B receptors was measured in the anterior leaflet. Cardiac anatomy and function were assessed by echocardiography. Results: Compared to C57BL/6J, FVB mice strains did not significantly differ regarding body weight increase, arterial blood pressure and heart rate. A progressive augmentation of plasma pro-ANP was observed in FVB mice. Nevertheless, no cardiac hypertrophy or left-ventricular fibrosis were observed. Accordingly, plasma TGF-β1 was not different among the three strains. Conversely, FVB mice demonstrated a high prevalence of fibromyxoid highly cellularized and enriched in glycosaminoglycans lesions, inducing major mitral leaflets thickening without increase in length. The increased thickness was correlated with urinary 5-HIAA and blood platelet count. Whole blood serotonin concentration was similar in the two strains but, in FVB, a reduction of plasma serotonin was observed together with an increase of the bleeding time. Finally, echocardiography identified left atrial and left ventricular remodeling associated with thickening of both mitral leaflets and mitral insufficient in 30% of FVB mice but no systolic protrusion of mitral leaflets towards the atrium. Conclusion: The FVB mouse strain is highly prone to spontaneous mitral myxomatous degeneration. A contribution of the peripheral serotonergic system is suggested.
- 2 September 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (9) , e0257022
Open AccessCharacterization of the spontaneous degenerative mitral valve disease in FVB mice
Background: The development of new non-surgical treatments dedicated to mitral valve degeneration is limited by the absence of relevant spontaneous and rapidly progressing animal experimental models. Animals: We characterized the spontaneous mitral valve degeneration in two inbred FVB mouse strains compared to C57BL/6J and investigated a contribution of the serotonergic system. Methods: Males and females FVB/NJ and FVB/NRj were compared to the putative C57BL/6J control at 12, 16, 20 and 24 weeks of age. Body weight, systolic blood pressure, heart rate, urinary 5-hydroxyindoleacetic acid (5-HIAA), whole blood and plasma serotonin, tail bleeding time, blood cell count, plasma TGF-β1 and plasma natriuretic peptide concentrations were measured. Myocardium and mitral valves were characterized by histology. mRNA mitral expression of 5-HT2A and 5-HT2B receptors was measured in the anterior leaflet. Cardiac anatomy and function were assessed by echocardiography. Results: Compared to C57BL/6J, FVB mice strains did not significantly differ regarding body weight increase, arterial blood pressure and heart rate. A progressive augmentation of plasma pro-ANP was observed in FVB mice. Nevertheless, no cardiac hypertrophy or left-ventricular fibrosis were observed. Accordingly, plasma TGF-β1 was not different among the three strains. Conversely, FVB mice demonstrated a high prevalence of fibromyxoid highly cellularized and enriched in glycosaminoglycans lesions, inducing major mitral leaflets thickening without increase in length. The increased thickness was correlated with urinary 5-HIAA and blood platelet count. Whole blood serotonin concentration was similar in the two strains but, in FVB, a reduction of plasma serotonin was observed together with an increase of the bleeding time. Finally, echocardiography identified left atrial and left ventricular remodeling associated with thickening of both mitral leaflets and mitral insufficient in 30% of FVB mice but no systolic protrusion of mitral leaflets towards the atrium. Conclusion: The FVB mouse strain is highly prone to spontaneous mitral myxomatous degeneration. A contribution of the peripheral serotonergic system is suggested.
- 13 March 2021
- Published by Springer Nature
- p. 213-229
The Discovery of 5-HT2B Receptor Pharmacology Through the Understanding of Drug-Induced Valvulopathy
- 13 March 2021
- Published by Springer Nature
- p. 213-229
The Discovery of 5-HT2B Receptor Pharmacology Through the Understanding of Drug-Induced Valvulopathy
- 1 February 2019
- Published by Elsevier in Pharmacological Research
- Vol. 140, 33-42
Serotonin contribution to cardiac valve degeneration: new insights for novel therapies?
- 1 February 2019
- Published by Elsevier in Pharmacological Research
- Vol. 140, 33-42
Serotonin contribution to cardiac valve degeneration: new insights for novel therapies?
- 8 January 2019
- Published by Springer Nature in Drugs
- Vol. 79 (2) , 125-142
Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options
Neuromyelitis optica (NMO) is an inflammatory and demyelinating disease of the central nervous system. Although the prevalence of NMO is low, the rapid and severe impairment observed in patients has led to extensive development of research in the fields of diagnostic criteria and therapy in the past 15 years. With improved understanding of the pathophysiology of NMO and the role of aquaporin-4 (AQP4) or myelin oligodendrocyte glycoprotein antibodies, numerous therapeutic approaches have been proposed and are currently undergoing evaluation. In this review, we describe the rationale for existing therapeutics and their benefit/risk ratio. We also discuss the pharmacological and clinical interest of future approaches targeting, among others, B or T cells, the blood–central nervous system barrier, complement, polynuclear cells, AQP4-antibody linkage and AQP4 activity. The numerous agents under development are the result of a major collaborative effort all over the world. After the considerable progress on diagnosis, we are now close to class I evidence for a therapeutic effect of several drugs in NMO spectrum disorders, most notably with the anti-interleukin-6 receptor antibody (satralizumab) and anti-complement-5 antibody (eculizumab).
- 8 January 2019
- Published by Springer Nature in Drugs
- Vol. 79 (2) , 125-142
Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options
Neuromyelitis optica (NMO) is an inflammatory and demyelinating disease of the central nervous system. Although the prevalence of NMO is low, the rapid and severe impairment observed in patients has led to extensive development of research in the fields of diagnostic criteria and therapy in the past 15 years. With improved understanding of the pathophysiology of NMO and the role of aquaporin-4 (AQP4) or myelin oligodendrocyte glycoprotein antibodies, numerous therapeutic approaches have been proposed and are currently undergoing evaluation. In this review, we describe the rationale for existing therapeutics and their benefit/risk ratio. We also discuss the pharmacological and clinical interest of future approaches targeting, among others, B or T cells, the blood–central nervous system barrier, complement, polynuclear cells, AQP4-antibody linkage and AQP4 activity. The numerous agents under development are the result of a major collaborative effort all over the world. After the considerable progress on diagnosis, we are now close to class I evidence for a therapeutic effect of several drugs in NMO spectrum disorders, most notably with the anti-interleukin-6 receptor antibody (satralizumab) and anti-complement-5 antibody (eculizumab).